See related Paraplatin powd for inj information 
 
Manufacturer Bristol-Myers Squibb 
Distributor Hong Kong: DKSH/Macau: Four Star 
Contents Carboplatin
Indications 1st-line treatment of advanced epithelial ovarian carcinoma. 2nd-line therapy after other chemotherapies have failed. Treatment of small-cell carcinoma of the lung & epidermoid carcinoma of the head & neck.
Click to view Paraplatin detailed prescribing infomation
Dosage Adult Previously untreated patient 400 mg/m2 as a single slow IV infusion for 15-60 min. A subsequent dose should not be given before 4 wk &/or until neutrophil count ≥2,000/mm2 & platelet count ≥100,000/mm2. Patient w/ CrCl 41-59 mL/min Initial dose: 250 mg/m2 IV, 16-40 mL/min Initial dose: 200 mg/m2 IV.
Click to view Paraplatin detailed prescribing infomation
Overdosage View Paraplatin overdosage for action to be taken in the event of an overdose.
Contraindications Hypersensitivity to platinum compd or mannitol. Severe kidney impairment, severe myelosuppression & bleeding tumors. Pregnancy & lactation.
Click to view Paraplatin detailed prescribing infomation
Warnings For additional cautionary notes to warn of the potential risk of using the medicine... click to view Paraplatin detailed prescribing infomation
Special Precautions Monitor kidney, liver, hematic (before therapy & wkly thereafter) & neurologic function. Renal impairment. Concurrent therapy w/ aminoglycosides & other nephrotoxic or ototoxic agents. May cause thrombocytopenia, leukopenia & anemia. Elderly. Childn.
Click to view Paraplatin detailed prescribing infomation
Adverse Drug Reactions Bone marrow suppression, blood dyscrasias, nausea, vomiting, peripheral neuropathies, nephrotoxicity, hepatic toxicity, ototoxicity, serum electrolyte disturbances, rash, urticaria, erythema, pruritus, inj site reactions, pain, asthenia, alopecia; CV, resp, genitourinary & mucosal side effects.
View ADR Monitoring Form
Drug Interactions Nephrotoxic agents.
View more drug interactions with Paraplatin
Pregnancy Category (US FDA)      
     
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). 
Caution For Usage For caution against possible variation of physical aspect of medicine... click to view Paraplatin detailed prescribing infomation
Description View Paraplatin description for details of the chemical structure and excipients (inactive components).
Mechanism of Action View Paraplatin mechanism of action for pharmacodynamics and pharmacokinetics details.
ATC Classification L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer. 

Presentation/Packing
Form Packing Photo
Paraplatin powder for injection  Paraplatin 150 mg/15 mL x 1's
 

 
Manufacturer: Bristol-Myers Squibb
 
Distributor: Hong Kong: DKSH
Macau: Four Star